Reuters - Teva Pharmaceutical Industries Ltd's clinical trials of its Parkinson's drug Azilect left U.S. drug reviewers unconvinced that the treatment slows the disease's progression.
You are here:
Health 
Diseases & Conditions FDA reviewers unconvinced on Teva Parkinson's drug
(Reuters)
Diseases & Conditions FDA reviewers unconvinced on Teva Parkinson's drug
(Reuters)
